COVID 19 Clinical Trial
Official title:
A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications
Verified date | July 2020 |
Source | Max Healthcare Insititute Limited |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The novel coronavirus disease (COVID-19), which began in Wuhan, China, in December 2019, has been declared to be a pandemic by the World Health Organization (WHO), Caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), COVID-19 has resulted in 1,781,127 cases and 108,994 deaths globally (till 12th April, 2020), affecting 199 countries and 2 international conveyances. US FDA has recently approved Convalescent Plasma from patients recovered from COVID 19 for the treatment of severe or life threatening COVID-19 infections. In a small case series, five critically ill COVID-19 patients with ARDS were treated with convalescent plasma containing neutralizing antibodies. Infusion of plasma was followed by improvement in clinical status in all five patients, with no deaths and the study reported that three patients were discharged, whilst two continued to be stable on mechanical ventilation. We designed this phase II, open label, randomized clinical trial with the primary objective to assess the safety and efficacy of the therapy in the second stage.
Status | Active, not recruiting |
Enrollment | 100 |
Est. completion date | August 9, 2021 |
Est. primary completion date | August 9, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility |
Inclusion Criteria: - 1. Patients admitted with RT-PCR confirmed COVID-19 illness. 2. Age > 18 years 3. Written informed consent 4. Has any of the two 1. PaO2/ FiO2 <300 2. Respiratory Rate > 24/min and SaO2 < 93% on room air Or In case of Severe or immediately life-threatening COVID-19, for example: a. Severe disease is defined as: i. dyspnea, ii. respiratory frequency = 30/min, iii. blood oxygen saturation = 93%, iv. partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300, and/or v. lung infiltrates > 50% within 24 to 48 hours b. Life-threatening disease is defined as: i. respiratory failure, ii. septic shock, and/or iii. multiple organ dysfunction or failure Exclusion Criteria: - 1. Pregnant women 2. Breastfeeding women 3. Known hypersensitivity to blood products 4. Receipt of Pooled Immunoglobulin in last 30 days 5. Participating in any other clinical trial 6. Clinical status precluding infusion of blood products |
Country | Name | City | State |
---|---|---|---|
India | Max Super Speciality hospital, Saket (A unit of Devki Devi Foundation) | New Delhi | Delhi |
Lead Sponsor | Collaborator |
---|---|
Max Healthcare Insititute Limited |
India,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary outcome is a composite measure of the avoidance of - 1. Progression to severe ARDS (P/F ratio 100) and 2. All-cause Mortality at 28 days | Baseline data about the demography, clinical presentations, ongoing medical therapy, and clinical history of participants in both arms will be collected and compared. Response to convalescent plasma will be coded as a binary outcome - based on whether the composite primary end point is met or not. All the statistical tests will be done at 5% level of significance and SPSS21 will be used for calculations. | depends on the total treatment time of the subjects within one year period of the trial. | |
Secondary | Time to symptom resolution-Fever,Shortness of Breath,Fatigue | Data from both arm will be collected and compared time to time | one year | |
Secondary | Hospital length of stay | total time of stay at hospital for the treatment and cure will be calculated and compared of both the arms | one year | |
Secondary | Change in SOFA pre and post transfusion | sepsis-related organ failure assessment (SOFA) score will be calculated for both the arms and compared for the analysis. | one year | |
Secondary | Duration of respiratory support required a. Duration of Invasive Mechanical Ventilation b. Duration of Non-Invasive | Most COVID patients admitted to intensive care require some form of respiratory support. Whether or not the plasma therapy decreases the duration of respiratory support and its comparison with the standard care therapy will be calculated. | one year | |
Secondary | Radiological improvement | Comparison between group response rates will be analyzed by radiological imaging and reported. | one year | |
Secondary | Adverse events (AE) associated with transfusion | Adverse events associated with infusion of convalescent plasma will also be descriptively summarized and compared with the adverse events experienced by participants receiving standard of care. | one year | |
Secondary | To measure the change in RNA levels (Ct values) of SARS-CoV-2 from RT-PCR [Time Frame: Days 0, 1, 3, and 7 after transfusion] | Ct values from day 0, 1, 3 & 7 will be calculated by RT-PCR and compared to check the response of therapy on the viral load. All the statistical tests will be done at 5% level of significance and SPSS21 will be used for calculations. | one year | |
Secondary | Levels of bio-markers pre and post transfusion | Bio-markers can play a role in understanding how existing drugs can be used to treat Covid-19. Hence, pre and post Plasma transfusion the level of bio-markers will be checked and compared. | one year | |
Secondary | Need of Vasopressor use | For critically ill subjects in both the arms the need of vasopressor will be compared. All these comparisons are for qualitative data and will be assessed for statistical significance by Fisher exact test in view of the small sample size. | one year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04333732 -
CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION
|
Phase 3 | |
Completed |
NCT04357457 -
Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia
|
Phase 3 | |
Terminated |
NCT04435795 -
Inhaled Ciclesonide for Outpatients With COVID19
|
Phase 2/Phase 3 | |
Completed |
NCT04357444 -
Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19
|
Phase 2 | |
Completed |
NCT04357834 -
WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
|
||
Not yet recruiting |
NCT05052320 -
Audiological Assessment of Recovered Covid 19 Subjects.
|
||
Withdrawn |
NCT04426344 -
Core Warming of COVID-19 Patients
|
N/A | |
Recruiting |
NCT05595031 -
Evaluation of the Clinical Impact of Corticosteroid Duration on SARS-CoV-2 (COVID-19 WHO)
|
||
Terminated |
NCT04371978 -
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
|
Phase 3 | |
Terminated |
NCT04401410 -
Anti-SARS Cov-2 T Cell Infusions for COVID 19
|
Phase 1 | |
Completed |
NCT04445337 -
Stellate Ganglion Blockade in COVID-19 Positive Patients
|
N/A | |
Completed |
NCT04403243 -
COLchicine Versus Ruxolitinib and Secukinumab in Open-label Prospective Randomized Trial in Patients With COVID-19
|
Phase 2 | |
Completed |
NCT04375644 -
Impact of the COVID-19 Pandemic on the Quality of Psychological Life (COVID-PRO-IMPACT)
|
||
Completed |
NCT04394078 -
Impact of COVID-19 Pandemic on Depression and Quality of Life
|
||
Recruiting |
NCT04407923 -
Drug Management of Juvenile Idiopathic Arthritis in Covid-19 Context : Impact on Therapeutical Managment
|
||
Withdrawn |
NCT04519411 -
Transpulmonary Pressure Measurements in Intubated Children With Covid-19 Respiratory Failure
|
N/A | |
Completed |
NCT04426305 -
Community Health Workers Against COVID19
|
N/A | |
Recruiting |
NCT04492514 -
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflation
|
Phase 2 | |
Completed |
NCT04399980 -
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
|
Phase 2 | |
Completed |
NCT04403828 -
Impact of COVID-19 on Personal Protection Among Dentist in Egypt
|